Probiotics for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 7, 2020, Pages

  Limketkai, Berkeley N ^a   Akobeng, Anthony K ^b   Gordon, Morris ^c   Adepoju, Akinlolu Adedayo ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^c UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; METRONIDAZOLE; PLACEBO;

BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM; CLINICAL EFFECTIVENESS; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LACTOBACILLUS RHAMNOSUS; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; INTESTINE FLORA; META ANALYSIS; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM LONGUM; CIPROFLOXACIN; CROHN DISEASE; GASTROINTESTINAL MICROBIOME; HUMANS; LACTOBACILLUS RHAMNOSUS; METRONIDAZOLE; PLACEBOS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 85088242958     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006634.pub3     Document Type: Review

References (36)

1. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterology 2004;4(5). x-wiley/crsRef/14168438 [PMID: 15113451]
2. Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Alimentary Pharmacology & Therapeutics 2010;32(7):872-83. x-wiley/crsRef/14168440 [PMID: 20735782]
3. ACTRN12614000465651. Single centre, open label Phase 1/Phase 2 study to evaluate the safety and efficacy of Dietzia C79793-74 in moderate to severe Crohn's disease. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366224 (first received 30 May 2019). x-wiley/crsRef/14168442
4. Day AS, Leach ST, Lemberg DA, Judd TA, Baba K, Hill RJ. The probiotic VSL#3 in children with active Crohn disease. Gastroenterology 2012;142(5):S-378. x-wiley/crsRef/14168444
5. NCT00367705. Double-blind placebo controlled trial of VSL#3 in children with Crohn's disease. clinicaltrials.gov/show/NCT00367705 (first received 30 May 2019). x-wiley/crsRef/14168446
6. NCT00374374. Treatment with Lactobacillus rhamnosus and Lactobacillus acidophilus for patients with active colonic Crohn’s disease. clinicaltrials.gov/show/NCT00374374 (first received 30 May 2019). x-wiley/crsRef/14168448
7. NCT01548014. The effect of a probiotic preparation (VSL#3) plus infliximab in children with Crohn's disease. clinicaltrials.gov/show/NCT01548014 (first received 30 May 2019). x-wiley/crsRef/14168450
8. Plein K, Hotz J. Therapeutic effects if Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhoea - a pilot study. Zeitschrift für Gastroenterologie 1993;31(2):129-34. x-wiley/crsRef/14168452 [PMID: 8465554]
9. Su H, Kang Q, Wang H, Yin H, Duan L, Liu Y, et al. Effects of glucocorticoids combined with probiotics in treating Crohn's disease on inflammatory factors and intestinal microflora. Experimental and Therapeutic Medicine 2018;16(4):2999-3003. x-wiley/crsRef/14168454 [PMID: 30214517]
10. Ye J, Wang W, Wu M, Zhang J. Suffasalarin combined with probiotics for treatment of patients with inflammatory bowel disease: effect on prognosis and inflammatory factors. World Chinese Journal of Digestology 2017;25(3):293-7. x-wiley/crsRef/14168456
11. Yılmaz İ, Dolar ME, Özpınar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology 2019;30(3):242-53. x-wiley/crsRef/14168458
12. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006634.pub2]
13. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000;118:A4179.
14. Click B, Regueiro M. Managing risks with biologics. Current Gastroenterology Reports 2019;21:1.
15. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010;362:1383-95.
16. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proceedings of the National Academy of Sciences of the United States of America 2007;104:7617-21.
17. Veritas Health Innovation Covidence. Version Accessed 10 January 2019. Melbourne, Australia: Veritas Health Innovation.Available at covidence.org.
18. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digestive Diseases and Sciences 2000;45:1462-4.
19. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.
20. Iheozor-Ejiofor Z, Kaur L, Gordon M, Baines PA, Sinopoulou V, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2020, Issue 3. [DOI: 10.1002/14651858.CD007443.pub3]
21. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clinical & Experimental Allergy 2000;30:1605-10.
22. Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2020, Issue 3. [DOI: 10.1002/14651858.CD005573.pub3]
23. Lai HH, Chiu CH, Kong MS, Chang CJ, Chen CC. Probiotic Lactobacillus casei: effective for managing childhood diarrhea by altering gut microbiota and attenuating fecal inflammatory markers. Nutrients 2019;11(5).
24. Limketkai BN, Parian AM, Chen PH, Colombel JF. Treatment with biologic agents has not reduced surgeries among patients with Crohn's disease with short bowel syndrome. Clinical Gastroenterology and Hepatology 2017;15:1908-14.
25. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalenceof the inflammatory bowel diseases with time, based onsystematic review. Gastroenterology 2012;142:46–54.
26. Mukherjee S, Ramesh A. Bacteriocin-producing strains of Lactobacillus plantarum inhibit adhesion of Staphylococcus aureus to extracellular matrix: quantitative insight and implications in antibacterial therapy. Journal of Medical Microbiology 2015;64:1514-26.
27. Navarro-López V, Ramírez-Boscá A, Ramón-Vidal D, Ruzafa-Costas B, Genovés-Martínez S, Chenoll-Cuadros E, Carrión-Gutiérrez M, Horga de la Parte J, Prieto-Merino D, Codoñer-Cortés FM. Effect of oral administration of a mixture of probiotic strains on SCORAD Index and use of topical steroids in young patients with moderate atopic dermatitis: a randomized clinical trial. JAMA Dermatology 2018;154(1):37-43.
28. Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database of Systematic Reviews 2019, Issue 11. [DOI: 10.1002/14651858.CD001176.pub5]
29. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. American Journal of Gastroenterology 2000;95(1 Suppl):S11-13.
30. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan 5). Version 5.4. Copenhagen, Denmark: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.
31. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Current Opinion in Gastroenterology 2005;21:44-50.
32. Schmidt RM, Pilmann Laursen R, Bruun S, Larnkjaer A, Mølgaard C, Michaelsen KF, Høst A. Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. Pediatric Allergy and Immunology 2019;30(3):335-40.
33. Schünemann H, Hill S, Guyatt G, et al. The GRADE approach and Bradford Hill's criteria for causation. Journal of Epidemiology & Community Health 2011;65:392-5.
34. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflammatory Bowel Disease 2000;6:107-15.
35. Shen J, Zuo ZX, Mao A. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflammatory Bowel Disease 2014;20:21-35.
36. Shouval DS, Rufo PA. The role of environmental factors in the pathogenesis of inflammatory bowel diseases: a review. JAMA Pediatrics 2017;171(10):999-1005.